Prophylactic Platelet Transfusions in Acute Myeloid Leukemia

Publisher Website
Google Scholar
Abstract
The December 25 issue of the Journal presents two important prospective, controlled studies on the use of platelet transfusions.1,2 Both studies, as commented on in an editorial in the same issue,3 could change transfusion policies. Leukocyte-depleted or ultraviolet B–irradiated pooled platelet products could replace single-donor–apheresis products because of their lower production costs, and the standard transfusion trigger could be lowered to 10×109 platelets per liter. Though carefully designed, both studies in our view missed some important points.